On the public citation graph
Anti-spasticity agents for multiple sclerosis
0 signed · 370 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archneur.1977.00500190056008openalex-snapshot
Baclofen, A New Antispastic Drug
inferredcites →https://doi.org/10.1001/archneur.1980.00500550062008openalex-snapshot
Phenytoin and Chlorpromazine in the Treatment of Spasticity
inferredcites →https://doi.org/10.1001/archneur.1987.00520220039013openalex-snapshot
The GABA-Agonist Progabide for Spasticity in Multiple Sclerosis
inferredcites →https://doi.org/10.1001/archneur.1992.00530330045014openalex-snapshot
An Antispasticity Effect of Threonine in Multiple Sclerosis
inferredcites →https://doi.org/10.1001/archneur.1994.00540150090022openalex-snapshot
4-Aminopyridine in the Treatment of Patients With Multiple Sclerosis
inferredcites →https://doi.org/10.1001/archneur.1997.00550180049011openalex-snapshot
Relationship of the Antispasticity Effect of Tizanidine to Plasma Concentration in Patients With Multiple Sclerosis
inferredcites →https://doi.org/10.1001/jama.1975.03260100016002openalex-snapshot
Treatment of Spasticity in Multiple Sclerosis With Dantrolene
inferredcites →https://doi.org/10.1001/jama.233.10.1046bopenalex-snapshot
Letter: Treatment of spasticity in multiple sclerosis with dantrolene
inferredcites →https://doi.org/10.1002/(sici)1097-4598(200001)23:1<98::aid-mus13>3.0.co;2-bopenalex-snapshot
Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis
inferredcites →https://doi.org/10.1002/ana.410130302openalex-snapshot
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
inferredcites →https://doi.org/10.1002/ana.410280407openalex-snapshot
Treatment of spasticity with botulinum toxin: A double‐blind study
inferredcites →https://doi.org/10.1002/j.1552-4604.1981.tb02621.xopenalex-snapshot
Treatment of Human Spasticity with Δ9‐Tetrahydrocannabinol
inferredcites →https://doi.org/10.1002/sim.4780132313openalex-snapshot
A meta‐analysis of clinical trials involving different classifications of response into ordered categories
inferredcites →https://doi.org/10.1007/978-3-7091-9029-6_9openalex-snapshot
Use of Intrathecal Baclofen Administered by Programmable Infusion Pumps in Resistent Spasticity
inferredcites →https://doi.org/10.1007/bf00243659openalex-snapshot
Die Wirkung des Chlorpromazin auf die Hemmungsprozesse im R�ckenmark bei Kranken mit spastischen L�hmungen
inferredcites →https://doi.org/10.1007/bf00314294openalex-snapshot
The effect of intrathecal baclofen on electrical muscle activity in spasticity
inferredcites →https://doi.org/10.1007/bf00314410openalex-snapshot
Effect of cannabinoids on spasticity and ataxia in multiple sclerosis
inferredcites →https://doi.org/10.1007/bf00544016openalex-snapshot
Tizanidine ? Initial pharmacokinetic studies in patients with spasticity
inferredcites →https://doi.org/10.1007/bf00866925openalex-snapshot
Clonidine in the treatment of spasticity in patients with multiple sclerosis
inferredcites →https://doi.org/10.1007/bf01061374openalex-snapshot
Tizanidine in the treatment of spasticity
inferredcites →https://doi.org/10.1007/pl00009796openalex-snapshot
Reduktion der spastischen Muskeltonuserhöhung bei Multipler Sklerose durch das Nonopioidanalgetikum Flupirtin
inferredcites →https://doi.org/10.1007/s001150050700openalex-snapshot
Optimierte Therapie des spastischen Syndroms durch Kombination von intrathekalem Baclofen mit Botulinumtoxin
inferredcites →https://doi.org/10.1007/s004820050239openalex-snapshot
Reduction of spastic increased muscle tone in multiple sclerosis by the nonopioid analgesic flupirtine
inferredcites →https://doi.org/10.1016/0003-9993(94)90337-9openalex-snapshot
Intrathecal baclofen for treatment of intractable spinal spasticity
inferredcites →https://doi.org/10.1016/0014-4886(89)90078-2openalex-snapshot
Short-term effects of intrathecal baclofen in spasticity
inferredcites →https://doi.org/10.1016/0021-9681(69)90086-1openalex-snapshot
Diazepam in the treatment of spasticity
inferredcites →https://doi.org/10.1016/0022-510x(71)90089-xopenalex-snapshot
The action of a GABA derivative in human spasticity
inferredcites →https://doi.org/10.1016/0022-510x(74)90137-3openalex-snapshot
A comparison of baclofen and diazepam in the treatment of spasticity
inferredcites →https://doi.org/10.1016/0022-510x(82)90005-3openalex-snapshot
Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis
inferredcites →https://doi.org/10.1016/s0003-9993(00)90135-7openalex-snapshot
Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial
inferredcites →https://doi.org/10.1016/s0003-9993(21)01642-7openalex-snapshot
Functional Outcome after Delivery of Intrathecal Baclofen
inferredcites →https://doi.org/10.1016/s0003-9993(95)81256-3openalex-snapshot
Poster 117 Botulinum toxin A effectiveness against spasticity and muscle spasms
inferredcites →https://doi.org/10.1016/s0003-9993(96)90217-8openalex-snapshot
Intrathecal baclofen administration for control of severe spinal spasticity: Functional improvement and long-term follow-up
inferredcites →https://doi.org/10.1016/s0003-9993(97)90168-4openalex-snapshot
Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis
inferredcites →https://doi.org/10.1016/s0031-9406(10)60484-1openalex-snapshot
Measurement In Neurological Rehabilitation
inferredcites →https://doi.org/10.1016/s0033-3182(80)73129-8openalex-snapshot
Marihuana as a therapeutic agent for muscle spasm or spasticity
inferredcites →https://doi.org/10.1016/s0140-6736(85)90228-4openalex-snapshot
CONTINUOUS INTRATHECAL BACLOFEN FOR SEVERE SPASTICITY
inferredcites →https://doi.org/10.1016/s1388-2457(00)00352-7openalex-snapshot
The effect of baclofen on the transmission in spinal pathways in spastic multiple sclerosis patients
inferredcites →https://doi.org/10.1017/s0317167100023994openalex-snapshot
The Use of Baclofen in Treatment of Spasticity in Multiple Sclerosis
inferredcites →https://doi.org/10.1017/s0317167100027104openalex-snapshot
Tizanidine Versus Baclofen in the Treatment of Spasticity in Patients with Multiple Sclerosis
inferredcites →https://doi.org/10.1017/s0317167100038026openalex-snapshot
Treatment of Spasticity with Tizanidine in Multiple Sclerosis
inferredcites →https://doi.org/10.1017/s031716710003986xopenalex-snapshot
Long Term Intrathecal Baclofen Therapy in Patients with Intractable Spasticity
inferredcites →https://doi.org/10.1017/s0317167100040452openalex-snapshot
Intrathecal Baclofen Therapy for Adults with Spinal Spasticity: Therapeutic Efficacy and Effect on Hospital Admissions
inferredcites →https://doi.org/10.1017/s0317167100042244openalex-snapshot
Intrathecal Baclofen for Intractable Spinal Spasticity – a Double-blind Cross-over Comparison with Placebo in 6 Patients
inferredcites →https://doi.org/10.1034/j.1600-0404.2000.101004244x./openalex-snapshot
Effect of baclofen on gait in spastic MS patients
inferredcites →https://doi.org/10.1038/sc.1974.27openalex-snapshot
A comparison of dantrolene sodium and diazepam in the treatment of spasticity
inferredcites →https://doi.org/10.1038/sc.1991.7openalex-snapshot
Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury
inferredcites →https://doi.org/10.1046/j.1468-1331.2000.00142.xopenalex-snapshot
The effect of magnesium oral therapy on spasticity in a patient with multiple sclerosis
inferredcites →https://doi.org/10.1056/nejm198906083202303openalex-snapshot
Intrathecal Baclofen for Severe Spinal Spasticity
inferredcites →https://doi.org/10.1093/brain/124.4.826openalex-snapshot
Modulation of presynaptic inhibition and disynaptic reciprocal Ia inhibition during voluntary movement in spasticity
inferredcites →https://doi.org/10.1093/milmed/140.1.26openalex-snapshot
Spasmolytic Properties of Dantrolene Sodium: Clinical Evaluation
inferredcites →https://doi.org/10.1093/ptj/67.5.659openalex-snapshot
Variability and Reliability of the Pendulum Test for Spasticity Using a Cybex® II Isokinetic Dynamometer
inferredcites →https://doi.org/10.1097/00002060-199202000-00012openalex-snapshot
INTRATHECAL BACLOFEN
inferredcites →https://doi.org/10.1097/00002060-199809000-00020openalex-snapshot
GABAPENTIN FOR RELIEF OF SPASTICITY ASSOCIATED WITH MULTIPLE SCLEROSIS1
inferredcites →https://doi.org/10.1097/00003086-199303000-00003openalex-snapshot
Determinants of Muscle Function in the Spastic Lower Extremity
inferredcites →https://doi.org/10.1097/00007611-197107000-00011openalex-snapshot
The Use of Dantrolene Sodium in Disorders of the Central Nervous System
inferredcites →https://doi.org/10.1111/j.1365-2125.1976.tb00641.xopenalex-snapshot
A trial of brolitene in the treatment of spasticity.
inferredcites →https://doi.org/10.1111/j.1468-1331.1999.tb00038.xopenalex-snapshot
Use of spasmography to assess the effects of botulinum toxin type A in patients with lower‐limb spasticity
inferredcites →https://doi.org/10.1111/j.1600-0404.1970.tb05791.xopenalex-snapshot
GABA DERIVATIVE IN SPASTICITY (β-(4-Chlorophenyl)-γ-Aminobutyric Acid, Ciba 34.647-Bα)
inferredcites →https://doi.org/10.1111/j.1600-0404.1974.tb02790.xopenalex-snapshot
THE EFFECT OF DANTRIUM®* ON SPASTICITY IN MULTIPLE SCLEROSIS
inferredcites →https://doi.org/10.1111/j.1600-0404.1975.tb01366.xopenalex-snapshot
A DOUBLE-BLIND TRIAL WITH BACLOFEN (LIORESAL®) AND DIAZEPAM IN SPASTICITY DUE TO MULTIPLE SCLEROSIS
inferredcites →https://doi.org/10.1111/j.1600-0404.1979.tb02941.xopenalex-snapshot
Mode of action of dantrolene sodium in spasticity
inferredcites →https://doi.org/10.1111/j.1600-0404.1981.tb04404.xopenalex-snapshot
Effect of symptomatic therapy on motor difficulties in multiple sclerosis recorded by quantitative measurements of voluntary power
inferredcites →https://doi.org/10.1111/j.1600-0404.1982.tb03092.xopenalex-snapshot
Dantrolene sodium in chronic spasticity of varying etiology
inferredcites →https://doi.org/10.1111/j.1600-0404.1983.tb04544.xopenalex-snapshot
The acute effect of the GABA-agonist, THIP, on proprioceptive and flexor reflexes in spastic patients
inferredcites →https://doi.org/10.1111/j.1600-0404.1984.tb07802.xopenalex-snapshot
The clinical effect of the GABA-agonist, progabide, on spasticity
inferredcites →https://doi.org/10.1111/j.1600-0404.1985.tb03187.xopenalex-snapshot
Effect of clorazepate in spasticity and rigidity: a quantitative study of reflexes and plasma concentrations
inferredcites →https://doi.org/10.1111/j.1600-0404.1987.tb07916.xopenalex-snapshot
The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen
inferredcites →https://doi.org/10.1111/j.1600-0404.1988.tb05899.xopenalex-snapshot
Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients
inferredcites →https://doi.org/10.1111/j.1600-0404.1993.tb05353.xopenalex-snapshot
A double-blind study of L-threonine in patients with spinal spasticity
inferredcites →https://doi.org/10.1136/bmj.4.5778.15openalex-snapshot
Baclofen in the Treatment of Spasticity
inferredcites →https://doi.org/10.1136/jnnp.39.4.350openalex-snapshot
Comparison of dantrolene sodium and diazepam in the treatment of spasticity.
inferredcites →https://doi.org/10.1136/jnnp.43.12.1132openalex-snapshot
Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.
inferredcites →https://doi.org/10.1136/jnnp.44.11.1035openalex-snapshot
The assessment of drug treatment of spastic gait.
inferredcites →https://doi.org/10.1136/jnnp.44.4.334openalex-snapshot
The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration.
inferredcites →https://doi.org/10.1136/jnnp.45.10.923openalex-snapshot
Action of cyproheptadine in spastic paraparetic patients.
inferredcites →https://doi.org/10.1136/jnnp.52.8.933openalex-snapshot
Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.
inferredcites →https://doi.org/10.1136/jnnp.57.11.1355openalex-snapshot
Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).
inferredcites →https://doi.org/10.1136/jnnp.57.5.582openalex-snapshot
Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump.
inferredcites →https://doi.org/10.1136/jnnp.60.2.168openalex-snapshot
Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen.
inferredcites →https://doi.org/10.1136/jnnp.68.6.707openalex-snapshot
Botulinum toxin (Dysport(R)) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study
inferredcites →https://doi.org/10.1136/jnnp.73.6.705openalex-snapshot
Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role?
inferredcites →https://doi.org/10.1136/pgmj.51.599.615openalex-snapshot
Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis
inferredcites →https://doi.org/10.1159/000114906openalex-snapshot
Clonazepam, Baclofen and Placebo in the Treatment of Spasticity
inferredcites →https://doi.org/10.1159/000445347openalex-snapshot
Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy
inferredcites →https://doi.org/10.1177/003693306601100202openalex-snapshot
Oral Diazepam in the Treatment of Spasticity in Paraplegia a Double-Blind Trial and Subsequent Impressions
inferredcites →https://doi.org/10.1177/135245850000600209openalex-snapshot
Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients
inferredcites →https://doi.org/10.1183/09031936.95.08020230openalex-snapshot
The effects of the GABA agonist, baclofen, on sleep and breathing
inferredcites →https://doi.org/10.1185/03007998809111121openalex-snapshot
Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis
inferredcites →https://doi.org/10.1191/0269215503cr581oaopenalex-snapshot
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms
inferredcites →https://doi.org/10.1191/026921599677595404openalex-snapshot
A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity
inferredcites →https://doi.org/10.1212/wnl.18.1_part_1.69openalex-snapshot
The quantitative evaluation of intravenous methocarbamol in the relief of spasticity
inferredcites →https://doi.org/10.1212/wnl.19.5.510openalex-snapshot
Prazepam in the treatment of spasticity
inferredcites →https://doi.org/10.1212/wnl.23.12.1313openalex-snapshot
The effect of dantrolene sodium on spasticity in multiple sclerosis
inferredcites →https://doi.org/10.1212/wnl.26.5.441openalex-snapshot
An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions
inferredcites →https://doi.org/10.1212/wnl.28.11.1094openalex-snapshot
Baclofen for spasticity in multiple sclerosis Double‐blind crossover and three‐year study
inferredcites →https://doi.org/10.1212/wnl.33.11.1444openalex-snapshot
Rating neurologic impairment in multiple sclerosis
inferredcites →https://doi.org/10.1212/wnl.45.4.712openalex-snapshot
Botulinum toxin A for spasticity, muscle spasms, and rigidity
inferredcites →https://doi.org/10.1212/wnl.58.9.1404openalex-snapshot
Safety, tolerability, and efficacy of orally administered cannabinoids in MS
inferredcites →https://doi.org/10.1212/wnl.60.4.729-aopenalex-snapshot
Safety, tolerability, and efficacy of orally administered cannabinoids in MS
inferredcites →https://doi.org/10.1300/j251v07n01_04openalex-snapshot
Delta-9-THC in the Treatment of Spasticity Associated with Multiple Sclerosis
inferredcites →https://doi.org/10.1590/s0004-282x1988000400008openalex-snapshot
Oxcarbazepine and spasticity: further observations
inferredcites →https://doi.org/10.3171/jns.1990.72.3.0393openalex-snapshot
Chronic intrathecal baclofen administration for control of severe spasticity
inferredcites →https://doi.org/10.3171/jns.1992.77.2.0236openalex-snapshot
Intrathecal baclofen for spasticity of spinal origin: seven years of experience
inferredcites →https://doi.org/10.3171/jns.1993.78.2.0226openalex-snapshot
Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study
inferredcites →https://doi.org/10.3171/jns.1996.85.3.0452openalex-snapshot
Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity
inferredcites →https://doi.org/10.3928/0191-3913-19940901-03openalex-snapshot
Results of a Prospective Randomized Trial of Botulinum Toxin Therapy in Acute Unilateral Sixth Nerve Palsy
inferredcites →https://doi.org/10.5694/j.1326-5377.1976.tb140942.xopenalex-snapshot
BACLOFEN (LIORESAL) IN THE LONG‐TERM MANAGEMENT OF SPASTICITY
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4008159openalex-extracted
Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis: A Randomized, Placebo-Controlled Clinical Trial
inferred← citeshttps://doi.org/10.1002/14651858.cd004156.pub3openalex-snapshot
Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease
inferred← citeshttps://doi.org/10.1002/14651858.cd004156.pub4openalex-snapshot
Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease
inferred← citeshttps://doi.org/10.1002/14651858.cd008929.pub2openalex-snapshot
Interventions for managing skeletal muscle spasticity following traumatic brain injury
inferred← citeshttps://doi.org/10.1002/14651858.cd009974openalex-snapshot
Non pharmacological interventions for spasticity in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/14651858.cd009974.pub2openalex-snapshot
Non pharmacological interventions for spasticity in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/14651858.cd012622openalex-snapshot
Non-pharmacological interventions for chronic pain in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/14651858.cd012622.pub2openalex-snapshot
Non-pharmacological interventions for chronic pain in multiple sclerosis
inferred← citeshttps://doi.org/10.1002/14651858.cd013444.pub2openalex-snapshot
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
inferred← citeshttps://doi.org/10.1002/9781444322705.ch11openalex-snapshot
Palliative Nursing Care in other Neurological Conditions
inferred← citeshttps://doi.org/10.1002/biof.1936openalex-snapshot
Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases
inferred← citeshttps://doi.org/10.1002/brb3.367openalex-snapshot
Spasticity in multiple sclerosis and role of glatiramer acetate treatment
inferred← citeshttps://doi.org/10.1002/mds.22452openalex-snapshot
Botulinum neurotoxins for post‐stroke spasticity in adults: A systematic review
inferred← citeshttps://doi.org/10.1002/psb.684openalex-snapshot
Sativex: oromucosal cannabinoid spray for spasticity in MS
inferred← citeshttps://doi.org/10.1002/ptr.7263openalex-snapshot
Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews
inferred← citeshttps://doi.org/10.1007/400_015openalex-snapshot
Cell–cell communication by Endocannabinoids during Immune Surveillance of the Central Nervous System
inferred← citeshttps://doi.org/10.1007/978-0-85729-682-5_4openalex-snapshot
Physical Symptoms in Neurological Conditions
inferred← citeshttps://doi.org/10.1007/978-1-4471-2395-8_8openalex-snapshot
Symptomatic Treatment for Progressive Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/978-1-4471-6455-5_10openalex-snapshot
Neurodegeneration with Brain Iron Accumulation
inferred← citeshttps://doi.org/10.1007/978-1-4939-0261-3_3openalex-snapshot
Clinical Use of Botulinum Neurotoxin: Neuromuscular Disorders
inferred← citeshttps://doi.org/10.1007/978-1-59259-971-4_41openalex-snapshot
The Management of Pain in Spinal Malignancies
inferred← citeshttps://doi.org/10.1007/978-3-030-57369-0_8openalex-snapshot
Cannabinoid-Based Medicines and Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/978-3-211-33079-1_20openalex-snapshot
Intrathecal baclofen in current neuromodulatory practice: established indications and emerging applications
inferred← citeshttps://doi.org/10.1007/978-3-662-43487-1_33openalex-snapshot
Mittel zur Behandlung der multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/978-3-662-47186-9_32openalex-snapshot
Mittel zur Behandlung der multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/978-3-662-50351-5_35openalex-snapshot
Mittel zur Behandlung der multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/978-3-662-54630-7_35openalex-snapshot
Mittel zur Behandlung der multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/978-3-662-57386-0_35openalex-snapshot
Mittel zur Behandlung der multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/978-3-662-59046-1_36openalex-snapshot
Pharmakologische Behandlung der multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/978-3-662-62168-4_33openalex-snapshot
Pharmakologische Behandlung der multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/978-3-662-63825-5_34openalex-snapshot
Pharmakologische Behandlung der multiplen Sklerose
inferred← citeshttps://doi.org/10.1007/s00115-005-1888-7openalex-snapshot
Das endogene Cannabinoidsystem
inferred← citeshttps://doi.org/10.1007/s00415-006-0218-8openalex-snapshot
Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain
inferred← citeshttps://doi.org/10.1007/s00415-008-6021-yopenalex-snapshot
Muscle rupture caused by exacerbated spasticity in a patient with multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-015-7866-5openalex-snapshot
Walking improvements with nabiximols in patients with multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s00415-016-8304-zopenalex-snapshot
Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force
inferred← citeshttps://doi.org/10.1007/s00415-020-09739-xopenalex-snapshot
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study
inferred← citeshttps://doi.org/10.1007/s00482-006-0474-7openalex-snapshot
Respiratorische Insuffizienz durch Delta-9-Tetrahydrocannabinol bei tetraplegischem Patienten
inferred← citeshttps://doi.org/10.1007/s10072-006-0648-1openalex-snapshot
Pharmacologic management of spasticity in multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s10072-006-0649-0openalex-snapshot
Non-pharmacologic interventions for spasticity associated with multiple sclerosis
inferred← citeshttps://doi.org/10.1007/s10072-015-2392-xopenalex-snapshot
Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study
inferred← citeshttps://doi.org/10.1007/s10072-017-3078-3openalex-snapshot
Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study
inferred← citeshttps://doi.org/10.1007/s10072-020-04392-8openalex-snapshot
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study
inferred← citeshttps://doi.org/10.1007/s10072-021-05182-6openalex-snapshot
Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience
inferred← citeshttps://doi.org/10.1007/s10198-013-0537-5openalex-snapshot
Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)
inferred← citeshttps://doi.org/10.1007/s11910-001-0051-5openalex-snapshot
Evidence basis for treatment of spasticity
inferred← citeshttps://doi.org/10.1007/s11910-011-0214-yopenalex-snapshot
Gait Abnormalities in Multiple Sclerosis: Pathogenesis, Evaluation, and Advances in Treatment
inferred← citeshttps://doi.org/10.1007/s11910-014-0463-7openalex-snapshot
Botulinum Toxin for Symptomatic Therapy in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s11910-018-0814-xopenalex-snapshot
The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews
inferred← citeshttps://doi.org/10.1007/s13311-015-0383-5openalex-snapshot
Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s13670-015-0128-7openalex-snapshot
Multiple Sclerosis in the Elderly: Considerations in the Geriatric Population for Diagnosis and Management
inferred← citeshttps://doi.org/10.1007/s40265-013-0125-0openalex-snapshot
A Systematic Review of Pharmacological Pain Management in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s40265-014-0197-5openalex-snapshot
Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s40271-016-0173-0openalex-snapshot
A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1016/b978-0-12-801914-6.00026-xopenalex-snapshot
Symptomatic and Complementary Treatments
inferred← citeshttps://doi.org/10.1016/b978-0-12-809666-6.00005-8openalex-snapshot
The Endocannabinoid System and Human Brain Functions
inferred← citeshttps://doi.org/10.1016/b978-0-323-40196-8.00053-xopenalex-snapshot
Pharmacologic Management of Myofascial Pain
inferred← citeshttps://doi.org/10.1016/b978-0-323-89862-1.00026-xopenalex-snapshot
Brain metabolic responses to cannabis use in people with multiple sclerosis: Insights from [18F]-FDG positron emission tomography and functional MRI
inferred← citeshttps://doi.org/10.1016/b978-0-443-06916-1.00006-2openalex-snapshot
Case studies in neurological physiotherapy
inferred← citeshttps://doi.org/10.1016/b978-0-444-52001-2.00023-6openalex-snapshot
Symptomatic treatment and management of multiple sclerosis
inferred← citeshttps://doi.org/10.1016/b978-1-4160-4007-1.50129-2openalex-snapshot
Multiple Sclerosis
inferred← citeshttps://doi.org/10.1016/b978-1-4160-4928-9.00012-3openalex-snapshot
Clinical Trials of Botulinum Toxin in Adult Spasticity
inferred← citeshttps://doi.org/10.1016/b978-3-437-21542-1.50013-8openalex-snapshot
Neuropathischer Schmerz
inferred← citeshttps://doi.org/10.1016/b978-3-437-21544-5.00009-3openalex-snapshot
Neuropathischer Schmerz
inferred← citeshttps://doi.org/10.1016/b978-3-437-23671-6.00011-0openalex-snapshot
Erkrankungen des Bewegungsapparats
inferred← citeshttps://doi.org/10.1016/b978-3-437-23672-3.00011-1openalex-snapshot
Erkrankungen des Bewegungsapparats
inferred← citeshttps://doi.org/10.1016/b978-3-437-23673-0.00011-2openalex-snapshot
Erkrankungen des Bewegungsapparats
inferred← citeshttps://doi.org/10.1016/b978-343721541-4.50011-3openalex-snapshot
Neuropathischer Schmerz
inferred← citeshttps://doi.org/10.1016/j.artd.2015.12.002openalex-snapshot
Total knee arthroplasty in multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.biopha.2017.01.005openalex-snapshot
Comparative study of therapeutic response to baclofen vs tolperisone in spasticity
inferred← citeshttps://doi.org/10.1016/j.clineuro.2010.04.010openalex-snapshot
The place of the botulinum toxin in the management of multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.clinthera.2006.04.005openalex-snapshot
Managing the symptoms of multiple sclerosis: A multimodal approach
inferred← citeshttps://doi.org/10.1016/j.disamonth.2013.03.015openalex-snapshot
The rehabilitation of the multiple sclerosis patient
inferred← citeshttps://doi.org/10.1016/j.ehbc.2004.03.014openalex-snapshot
Cannabinoids do not reduce objective measurements in muscle spasticity, but people with multiple sclerosis perceive some benefit
inferred← citeshttps://doi.org/10.1016/j.ejpn.2007.08.002openalex-snapshot
Visual Analogue Scale to score the effects of Botulinum Toxin A treatment in children with cerebral palsy in daily clinical practice
inferred← citeshttps://doi.org/10.1016/j.expneurol.2010.03.030openalex-snapshot
The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis
inferred← citeshttps://doi.org/10.1016/j.gaitpost.2008.07.011openalex-snapshot
Gait analysis in multiple sclerosis: Characterization of temporal–spatial parameters using GAITRite functional ambulation system
inferred← citeshttps://doi.org/10.1016/j.jns.2004.04.002openalex-snapshot
Comfort care in severely disabled multiple sclerosis patients
inferred← citeshttps://doi.org/10.1016/j.jns.2014.09.030openalex-snapshot
3-week whole body vibration does not improve gait function in mildly affected multiple sclerosis patients—a randomized controlled trial
inferred← citeshttps://doi.org/10.1016/j.jocn.2017.02.044openalex-snapshot
Breakthroughs in the spasticity management: Are non-pharmacological treatments the future?
inferred← citeshttps://doi.org/10.1016/j.jpainsymman.2004.05.002openalex-snapshot
Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review
inferred← citeshttps://doi.org/10.1016/j.jsps.2017.04.041openalex-snapshot
RETRACTED: The comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury
inferred← citeshttps://doi.org/10.1016/j.msard.2011.11.001openalex-snapshot
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2015.10.007openalex-snapshot
Spasticity in multiple sclerosis: Associations with impairments and overall quality of life
inferred← citeshttps://doi.org/10.1016/j.msard.2017.06.015openalex-snapshot
Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation
inferred← citeshttps://doi.org/10.1016/j.msard.2018.10.009openalex-snapshot
Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience
inferred← citeshttps://doi.org/10.1016/j.msard.2020.102177openalex-snapshot
Nabiximols plus robotic assisted gait training in improving motor performances in people with Multiple Sclerosis.
inferred← citeshttps://doi.org/10.1016/j.msard.2024.105740openalex-snapshot
A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.msard.2025.106778openalex-snapshot
Understanding pain types and the lived experiences of individuals with multiple sclerosis and pain: A mixed methods study
inferred← citeshttps://doi.org/10.1016/j.ncl.2011.01.008openalex-snapshot
Symptomatic Management in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1016/j.ncl.2025.08.004openalex-snapshot
Placebo Responses in Trials for Multiple Sclerosis
inferred← citeshttps://doi.org/10.1016/j.neurol.2015.03.002openalex-snapshot
Une avancée pour la prise en charge de la spasticité dans la sclérose en plaques
inferred← citeshttps://doi.org/10.1016/j.neurol.2018.01.370openalex-snapshot
Treatment of progressive multiple sclerosis: Challenges and promising perspectives
inferred← citeshttps://doi.org/10.1016/j.nrl.2013.06.014openalex-snapshot
Experiencia clínica con los cannabinoides en la terapia de la espasticidad en la esclerosis múltiple
inferred← citeshttps://doi.org/10.1016/j.nrleng.2013.06.007openalex-snapshot
Clinical experiences with cannabinoids in spasticity management in multiple sclerosis
inferred← citeshttps://doi.org/10.1016/j.pmr.2005.01.006openalex-snapshot
Multiple Sclerosis and Spasticity
inferred← citeshttps://doi.org/10.1016/j.pmr.2005.12.005openalex-snapshot
Muscle Relaxants and Antispasticity Agents
inferred← citeshttps://doi.org/10.1016/j.pmr.2012.11.004openalex-snapshot
Ambulation and Multiple Sclerosis
inferred← citeshttps://doi.org/10.1016/j.tins.2005.03.006openalex-snapshot
Emerging properties of cannabinoid medicines in management of multiple sclerosis
inferred← citeshttps://doi.org/10.1016/s0211-3449(07)75465-6openalex-snapshot
Tratamiento sintom?tico de las complicaciones de la esclerosis m?ltiple. Tratamiento rehabilitador
inferred← citeshttps://doi.org/10.1016/s0889-857x(01)00004-7openalex-snapshot
The neuropharmacology of centrally-acting analgesic medications in fibromyalgia
inferred← citeshttps://doi.org/10.1016/s1474-4422(10)70249-0openalex-snapshot
Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions
inferred← citeshttps://doi.org/10.1016/s1474-4422(14)70231-5openalex-snapshot
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed
inferred← citeshttps://doi.org/10.1017/cbo9780511781698.020openalex-snapshot
Rehabilitation: sectorial interventions
inferred← citeshttps://doi.org/10.1017/cbo9781139023986.054openalex-snapshot
Therapy in clinical practice
inferred← citeshttps://doi.org/10.1017/cbo9781139023986.060openalex-snapshot
Management of spasticity
inferred← citeshttps://doi.org/10.1038/sj.sc.3101982openalex-snapshot
The treatment of spasticity with Δ9-tetrahydrocannabinol in persons with spinal cord injury
inferred← citeshttps://doi.org/10.1055/s-0038-1627352openalex-snapshot
Therapie der fokalen Spastik mit Botulinumtoxin
inferred← citeshttps://doi.org/10.1080/09638280600756141openalex-snapshot
Use of the International Classification of Functioning, Disability and Health (ICF) to identify preliminary comprehensive and brief core sets for multiple sclerosis
inferred← citeshttps://doi.org/10.1080/15440478.2013.878604openalex-snapshot
Therapeutic Potential of Cannabinoids—Perspectives for the Future
inferred← citeshttps://doi.org/10.1093/ageing/afj084openalex-snapshot
Biomechanical measurement of post-stroke spasticity
inferred← citeshttps://doi.org/10.1093/braincomms/fcac300openalex-snapshot
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial
inferred← citeshttps://doi.org/10.1093/med/9780198869696.003.0024openalex-snapshot
A–Z Index of neurological drugs
inferred← citeshttps://doi.org/10.1097/cnq.0000000000000303openalex-snapshot
Application of Cannabinoids in Neurosciences
inferred← citeshttps://doi.org/10.1097/htr.0000000000000094openalex-snapshot
Distribution of Lower Limb Spasticity Does Not Influence Mobility Outcome Following Traumatic Brain Injury
inferred← citeshttps://doi.org/10.1097/phm.0000000000000970openalex-snapshot
Effectiveness of Physiotherapy Interventions on Spasticity in People With Multiple Sclerosis
inferred← citeshttps://doi.org/10.1097/phm.0000000000002106openalex-snapshot
Are Cannabis and Cannabinoids Effective for Symptomatic Treatment in People With Multiple Sclerosis?
inferred← citeshttps://doi.org/10.1111/bph.13889openalex-snapshot
Big conductance calcium‐activated potassium channel openers control spasticity without sedation
inferred← citeshttps://doi.org/10.1111/cns.12358openalex-snapshot
Placebo Effects in a Multiple Sclerosis Spasticity Enriched Clinical Trial with the Oromucosal Cannabinoid Spray ( THC / CBD ): Dimension and Possible Causes
inferred← citeshttps://doi.org/10.1111/dmcn.12188openalex-snapshot
An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms
inferred← citeshttps://doi.org/10.1111/ene.13877openalex-snapshot
High‐frequency repetitive transcranial magnetic stimulation and intermittent theta‐burst stimulation for spasticity management in secondary progressive multiple sclerosis
inferred← citeshttps://doi.org/10.1111/j.1468-1331.2006.01639.xopenalex-snapshot
Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis
inferred← citeshttps://doi.org/10.1124/pr.58.3.2openalex-snapshot
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
inferred← citeshttps://doi.org/10.1136/bmj-2022-072348openalex-snapshot
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies
inferred← citeshttps://doi.org/10.1136/dtb.2012.11.0150openalex-snapshot
What place for ▼cannabis extract in MS?
inferred← citeshttps://doi.org/10.1136/jnnp-2015-312591openalex-snapshot
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
inferred← citeshttps://doi.org/10.1136/jnnp-2022-329886openalex-snapshot
Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study
inferred← citeshttps://doi.org/10.1136/practneurol-2011-000155openalex-snapshot
Spasticity: pathophysiology, evaluation and management
inferred← citeshttps://doi.org/10.1159/000357743openalex-snapshot
Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience
inferred← citeshttps://doi.org/10.11606/issn.2317-0190.v12i3a102532openalex-snapshot
Esclerose múltipla e exercício físico
inferred← citeshttps://doi.org/10.1177/0269215507072772openalex-snapshot
Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis
inferred← citeshttps://doi.org/10.1177/0269215508097298openalex-snapshot
Mental techniques during manual stretching in spasticity — a pilot randomized controlled trial
inferred← citeshttps://doi.org/10.1177/0888439002250449openalex-snapshot
Spasticity in Multiple Sclerosis
inferred← citeshttps://doi.org/10.1177/1179573519831997openalex-snapshot
Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
inferred← citeshttps://doi.org/10.1177/1352458506071509openalex-snapshot
The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis
inferred← citeshttps://doi.org/10.1177/1352458510367462openalex-snapshot
Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis
inferred← citeshttps://doi.org/10.1177/1352458510388680openalex-snapshot
The (AAT) n repeat of the cannabinoid CB 1 receptor gene influences disease progression in relapsing multiple sclerosis
inferred← citeshttps://doi.org/10.1177/1352458510395056openalex-snapshot
Intrathecal baclofen in multiple sclerosis: Too little, too late?
inferred← citeshttps://doi.org/10.1177/1478271520073702028openalex-snapshot
Current treatments for multiple sclerosis
inferred← citeshttps://doi.org/10.1177/1756285612453972openalex-snapshot
Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity
inferred← citeshttps://doi.org/10.1177/1756285613475835openalex-snapshot
Treatment failure of intrathecal baclofen and supra-additive effect of nabiximols in multiple sclerosis-related spasticity: a case report
inferred← citeshttps://doi.org/10.1177/1756285615612659openalex-snapshot
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis
inferred← citeshttps://doi.org/10.1177/20552173211022779openalex-snapshot
Effectiveness of massage therapy on fatigue and pain in patients with multiple sclerosis: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1179/016164106x98206openalex-snapshot
Treatment of symptoms in multiple sclerosis
inferred← citeshttps://doi.org/10.1179/016164109x12590518685660openalex-snapshot
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
inferred← citeshttps://doi.org/10.1179/108331905x68565openalex-snapshot
The effects of transcutaneous electrical nerve stimulation on spasticity
inferred← citeshttps://doi.org/10.1186/1471-2377-9-59openalex-snapshot
Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review
inferred← citeshttps://doi.org/10.1186/1745-6215-13-189openalex-snapshot
Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach
inferred← citeshttps://doi.org/10.1186/s12883-020-01902-1openalex-snapshot
MS Spasticity: Take Control (STC) for ambulatory adults: protocol for a randomized controlled trial
inferred← citeshttps://doi.org/10.1186/s12906-019-2803-2openalex-snapshot
Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
inferred← citeshttps://doi.org/10.1186/s12955-014-0119-yopenalex-snapshot
Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany
inferred← citeshttps://doi.org/10.1186/s13643-019-1243-xopenalex-snapshot
Benefits and harms of medical cannabis: a scoping review of systematic reviews
inferred← citeshttps://doi.org/10.1212/01.con.0000461092.86865.a4openalex-snapshot
Management of Chronic Spinal Cord Dysfunction
inferred← citeshttps://doi.org/10.12786/bn.2023.16.e19openalex-snapshot
The Efficacy of Spinal Cord Stimulators in the Reduction of Multiple Sclerosis Spasticity: A Narrative Systematic Review
inferred← citeshttps://doi.org/10.12968/bjnn.2009.5.9.44099openalex-snapshot
Spasticity management, part 2: Choosing the right medication to suit the individual
inferred← citeshttps://doi.org/10.12968/bjon.2006.15.1.20310openalex-snapshot
Multiple sclerosis: living the reality
inferred← citeshttps://doi.org/10.1371/journal.pone.0104165openalex-snapshot
Psychiatric Diagnoses, Medication and Risk for Disability Pension in Multiple Sclerosis Patients; a Population-Based Register Study
inferred← citeshttps://doi.org/10.1371/journal.pone.0180651openalex-snapshot
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)
inferred← citeshttps://doi.org/10.1371/journal.pone.0219670openalex-snapshot
The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
inferred← citeshttps://doi.org/10.1515/sjecr-2015-0047openalex-snapshot
Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze
inferred← citeshttps://doi.org/10.1517/14656566.2011.607162openalex-snapshot
Treating pain in multiple sclerosis
inferred← citeshttps://doi.org/10.1517/14712598.2012.721765openalex-snapshot
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis
inferred← citeshttps://doi.org/10.1517/17460441.2011.560935openalex-snapshot
A drug discovery case history of ‘delta-9-tetrahydrocannabinol, cannabidiol’
inferred← citeshttps://doi.org/10.1586/14737175.2013.865877openalex-snapshot
Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice
inferred← citeshttps://doi.org/10.1586/14737175.2015.1067607openalex-snapshot
Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis
inferred← citeshttps://doi.org/10.1586/14737175.7.9.1157openalex-snapshot
Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances
inferred← citeshttps://doi.org/10.1586/ecp.12.59openalex-snapshot
Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis
inferred← citeshttps://doi.org/10.1586/ern.11.25openalex-snapshot
Pathophysiology, assessment and management of multiple sclerosis spasticity: an update
inferred← citeshttps://doi.org/10.1586/ern.11.47openalex-snapshot
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
inferred← citeshttps://doi.org/10.1586/ern.12.10openalex-snapshot
Advances in the management of multiple sclerosis-related spasticity
inferred← citeshttps://doi.org/10.1586/ern.12.11openalex-snapshot
Clinical efficacy and effectiveness of Sativex®, a combined cannabinoid medicine, in multiple sclerosis-related spasticity
inferred← citeshttps://doi.org/10.1586/ern.12.12openalex-snapshot
Evaluation of the safety and tolerability profile of Sativex®: is it reassuring enough?
inferred← citeshttps://doi.org/10.1586/ern.13.10openalex-snapshot
Multiple sclerosis spasticity: ‘state-of-the-art’ questionnaire survey of specialized healthcare professionals
inferred← citeshttps://doi.org/10.1586/ern.13.2openalex-snapshot
Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials
inferred← citeshttps://doi.org/10.1586/ern.13.4openalex-snapshot
Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain
inferred← citeshttps://doi.org/10.1586/erp.11.6openalex-snapshot
Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study
showing the first 200 of 260 · page through all 260
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.